Clinical trials: Nausea and Vomiting Caused by Trastuzumab Deruxtecan
Nausea and Vomiting Caused by Trastuzumab Deruxtecan
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab Deruxtecan
This study aims to evaluate whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on nausea and vomiting induced by trastuzumab deruxtecan are non-inferior to the standard…
- Trial name
- ADTD Ⅱ (NCT07716189)
- Testing
- Auricular point stimulation plus dexamethasone, Standard pharmacologic antiemetic regimen
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Nausea and Vomiting Caused by Trastuzumab Deruxtecan
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan
The goal of this clinical trial is to learn if auricular point stimulation plus dexamethasone works to effectively prevent or suppress nausea and vomiting caused by trastuzumab deruxtecan in breast cancer palliative therapy.
- Trial name
- ADTD (NCT07537673)
- Testing
- Auricular point stimulation plus dexamethasone
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine